Skip to main content

Table 4 RFS in patients with a HR-positive or HR–negative tumor classified by clinical and genetic characteristics

From: Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy

  Hormone receptor-positive tumors (n=25) Hormone receptor-negative tumors (n=17)
  No. of Patients (No. of events) 3-year estimates 95% CI P-value No. of Patients (No. of events) 3-year estimates 95% CI P-value
All patients 25 (7) 0.76 0.58-0.95   17 (5) 0.69 0.42-0.95  
Response to neoadjuvant CT         
 pCR (grade 3) 8 (1) 0.81 0.58-1.05 0.485 12 (3) 1.0 - 0.906
 No pCR (grade 0~2) 14(4) 0.77 0.49-1.05   3 (1) 0.69 0.39-0.99  
HER2 copy numbers         
 ≤ 2.0 6 (4) 0.60 0.17-1.03 0.12 2 (1) 0.50 −0.19-1.19 NA
 > 2.0 19 (3) 0.81 0.62-1.01   15 (4) 0.74 0.47-1.00  
Wild-type HER2 mRNA         
 < 400 14 (5) 0.67 0.43-0.91 0.054 6 (3) 0.33 −0.17-0.83 0.196
 ≥ 400 6 (0) 1.0 -   11 (2) 0.86 0.60-1.12  
16HER2 mRNA         
 < 4.5 14 (4) 0.74 0.53-0.96 0.283 3 (1) 0 0 0.832
 ≥ 4.5 6 (1) 0.80 0.45-1.15   14 (4) 0.72 0.45-1.00  
Percentages of ∆16HER2 mRNA         
 < 2.4% 17 (3) 0.78 0.59-0.97 0.143 14 (3) 0.77 0.49-1.00 0.073
 ≥ 2.4% 3 (2) 0.67 0.13-1.20   3 (2) 0.33 −0.20-0.87  
PIK3CA (exons 9 and 20)         
 Wild-type 21 (4) 0.89 0.75-1.03 0.006 15 (5) 0.65 0.37-0.94 NA
 Mutated 4 (3) 0.25 −0.17-0.67   2 (0) 1.0 -  
PIK3CA (exons 9 and 20)         
 Wild-type + Norma l+ Loss +UPD 16 (1) 1.0 - 0.001 12 (5) 0.57 0.25-0.89 0.2
 Mutated + Gain 9 (6) 0.40 0.06-0.74   5 (0) 1.0 -  
PTEN         
 Normal + Gain + UPD 20 (6) 0.76 0.55-0.97 0.814 17 (5) 0.69 0.42-0.95 NA
 Loss 5 (1) 0.80 0.45-1.15   0 - -  
INPP4B         
 Normal + Gain + UPD 21 (4) 0.83 0.65-1.01 0.133 15 (4) 0.75 0.49-1.00 NA
 Loss 4 (3) 0.50 0.01-0.99   2 (1) 0.50 −0.19-1.19  
PI3KCA, PTEN, INPP4B         
 No aberrations* 12 (0) 1.0 - 0.002 10 (4) 0.59 0.23-0.95 0.312
 Aberrations** 13 (7) 0.60 0.32-0.87   7 (1) 0.75 0.33-1.17  
DEK         
 Normal 17 (3) 0.86 0.68-1.04 0.067 11 (2) 0.91 0.74-1.08 0.106
 Gain 8 (4) 0.51 0.11-0.91   6 (3) 0.30 −0.17-0.77  
FGFR1         
 Normal + Loss + UPD 17 (5) 0.72 0.49-0.96 0.94 12 (4) 0.59 0.28-0.91 0.69
 Gain 8 (2) 0.86 0.60-1.12   5 (1) 1.0 -  
CCND1         
 Normal + Loss 16 (2) 0.91 0.74-1.08 0.075 9 (2) 0.71 0.36-1.06 0.433
 Gain 9 (5) 0.51 0.16-0.85   8 (3) 0.67 0.29-1.04  
FOXA1         
 Normal + UPD 17 (1) 0.92 0.76-1.07 0.002 13 (5) 0.66 0.39-0.93 0.504
 Gain 8 (6) 0.45 0.08-0.82   4 (0) 1.0 -  
CDH3         
 Normal + Loss + UPD 20 (3) 0.88 0.73-1.04 0.007 17 (5) 0.69 0.42-0.95 NA
 Gain 5 (4) 0.40 −0.03-0.83   0 - -  
BIRC5         
 Normal + Loss + UPD 19 (3) 0.86 0.68-1.04 0.016 8 (2) 0.75 0.45-1.05 0.235
 Gain 6 (4) 0.44 0.01-0.88   9 (3) 0.59 0.10-1.09  
MYBL2         
 Normal + Loss 16 (2) 0.92 0.78-1.07 0.015 14 (5) 0.66 0.39-0.94 0.539
 Gain 9 (5) 0.48 0.11-0.84   3 (0) 1.0 -  
AIB1         
 Normal + Loss 17 (2) 0.93 0.79-1.06 0.006 14 (5) 0.66 0.39-0.94 0.539
 Gain 8 (5) 0.39 −0.01-0.78   3 (0) 1.0 -  
  1. CI, confidence interval; CT, chemotherapy; NA, not applicable; *No aberrations, wild-type and a normal copy of PIK3CA, a normal copy, gain, or UPD of PTEN or INPP4B; **Aberrations, mutated and/or gain of PIK3CA, and loss of PTEN or INPP4B.